CLX GI 62D2
Alternative Names: CLX-GI-62D2Latest Information Update: 28 Apr 2024
At a glance
- Originator Cellix Bio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Faecal incontinence
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Faecal-Incontinence in India
- 04 Mar 2020 Cellix Bio has multiple international patents, including in the US, covering its pipeline candidates (Cellix Bio website, March 2020)
- 04 Mar 2020 Preclinical trials in Faecal Incontinence in India (Cellix Bio pipeline, March 2020)